MMIP is divided into five workstreams, each working towards achieving the outcome of an internationally recognised, attractive and thriving environment for medicines manufacturing. All of these workstreams are supported by overarching communications work and building the manufacturing community to ensure it speaks with one voice.
The regulatory environment workstream is trying to maximise innovative processes by highlighting existing regulatory flexibility and the positive UK regulatory landscape to industry.
One of the ways it is doing this is by partnering with the Medicines and Healthcare Products Regulatory Agency (MHRA) to produce case studies on regulatory collaboration between medicines manufacturers and the MHRA Innovation Office. Further details on the MHRA Innovation Office and the case studies can be found here.
The skills workstream aims to foster a sustainable medicines manufacturing workforce and appropriate skills to support the growth of medicines manufacturing in the UK.
MMIP is supporting the Science Industry Partnership (SIP), which is co-funded by government and industry to develop a strategy for near term and future skills provision in the life sciences sector.
As part of this work, MMIP and the ABPI undertook a skills survey to provide information on skills need for the manufacture of medicines. These findings were discussed with Cogent, the UK’s strategic body for skills in the science industries, before being presented to SIP. This helped to secure £52m of investment in new and emerging science talent through the Science Industrial Partnership (SIP).
In May 2015 the MHRA, jointly with professional bodies, began a review of Qualified Persons data. This is to gather evidence to demonstrate the problem with the lack of Qualified Person skill sets in the medicines manufacturing industry.
Apprenticeships are growing in popularity in the medicines manufacturing sector - learn more from the GSK case studies.
Cogent have published some useful guides to employing apprentices and work experience students
The fiscal environment workstream focuses on developing fiscal incentives to encourage a more competitive environment for medicines manufacturing in the UK.
This includes a workshop with HM Revenue & Customs (HMRC) to explore the potential use of fiscal incentives, such as the patent box and research and development tax credits. A sector funding guide is also planned.
The supply chain workstream seeks to deliver capable and connected infrastructure, building understanding of medicines manufacturing supply chains, identifying opportunities to maximise supply and fostering non-competitive sector collaboration.
This includes a successful submission to the Advanced Manufacturing Supply Chain Initiative to develop new digital design and manufacturing processes for medicines. This project has the potential to propel the UK to the forefront of medicinal product design and manufacture through modelling and simulation in medicines development in order to reduce uncertainty and make better, faster and safer design and operating decisions.
Finally, the Knowledge Transfer Network is developing an innovation landscape portal, which will provide information on existing medicines manufacturers around the country, this is due to launch in Autumn 2015 at the annual bioProcessUK Conference.
The technology workstream seeks to understand and pursue the future needs of the medicines manufacturing industry.
Working with government agencies and academia, MMIP are identifying novel manufacturing technology areas, opportunities for their development and introduction in the UK and ways of facilitating this.
MMIP is putting resources towards a Medicines Manufacturing Innovation Centre, this aims to catalyse the implementation of new technology in both the pharmaceutical and fine chemical supply chains.
MMIP launched its Technology and Innovation Road Map in August 2016. This makes recommendations to protect and grow UK medicines manufacturing in order to maintain the UK’s leading position in an increasingly competitive global landscape. Specifically, it calls for strategic investment in complementary technology centres, funded through the Industrial Strategy Challenge Fund.